Lina Herhaus | Hepatocellular Carcinomia | Best Researcher Award

Assist Prof Dr. Lina Herhaus | Hepatocellular Carcinomia | Best Researcher Award

Helmholtz Center for Infection Research HZI | Germany

Author Profile

Scopus

Orcid ID

Google Scholar

🌟 BIOGRAPHY OF DR. LINA HERHAUS 🌟

Title: Trailblazer in Immune Signaling and Molecular Mechanisms 🌱🔬

🏫 EARLY ACADEMIC PURSUITS

Dr. Lina Herhaus’s journey into the world of science began during a transformative gap year in Mexico, where her exposure to research at ECOSUR ignited a fascination with genetics and molecular mechanisms. Driven by this passion, she pursued a degree in Molecular Biology, studying across Germany and the UK. She then advanced to complete her PhD at the MRC Protein Phosphorylation and Ubiquitylation Unit, where she honed her expertise in post-translational modifications.

👩‍🔬 PROFESSIONAL ENDEAVORS

Dr. Herhaus's career reflects a dedication to pushing the boundaries of molecular and immune research. After earning her PhD, she joined Professor Ivan Dikic’s lab in Frankfurt as an EMBO Long-Term Fellow, expanding her knowledge of cellular signaling and immunity. In 2020, she embarked on her independent research journey, founding the "Immune Signaling" group at Goethe University. Currently, she leads the Microbial Stargazing Program at HZI and serves as a W1 Professor at Hannover Medical School.

🔍 RESEARCH FOCUS AND INNOVATIONS ON HEPATOCELLULAR CARCINOMIA

Dr. Herhaus's lab explores:

  • Protein Homeostasis: Understanding cellular equilibrium.
  • Innate Immunity: Investigating the body's first line of defense.
  • Post-Translational Modifications: Decoding protein functionality.
  • Pathogen-Host Interactions: Illuminating the battle between microbes and hosts.
  • Vesicle Trafficking & Immune Evasion Mechanisms: Uncovering cellular transport and immune strategies.

Her team employs cutting-edge methods such as automated high-content microscopy, genetics, proteomics, molecular biology, and biochemical assays.

🌍 IMPACT AND INFLUENCE

Dr. Herhaus’s groundbreaking research has been pivotal in understanding cellular signaling pathways and immune responses, with implications in quality control, cancer biology, and host-pathogen dynamics. Her recognition extends to multiple honors, including the Tim Hunt Prize and the Signal Transduction Society Science Award.

📊 ACADEMIC CITATIONS

  • Total Citations: 2,070
  • H-Index: 18
  • i10-Index: 20

Her scholarly output highlights her influence, with contributions featured in esteemed publications and a forthcoming book chapter titled Targeting Autophagy as an Immunotherapy Strategy.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Herhaus is a rising star in molecular biology and immune research, with a vision to uncover new therapeutic avenues in cancer, immunity, and infection. Her leadership at HZI and Hannover Medical School ensures a continued impact, inspiring the next generation of scientists while advancing fundamental and translational science.

🔗 PROFESSIONAL AFFILIATIONS

  • Member of STS (Signal Transduction Society)
  • Member of GMB (Gesellschaft für Biochemie und Molekularbiologie) e.V.
  • Member of DHV (Deutscher Hochschulverband)

📑NOTABLE PUBLICATIONS 

"TBK1-mediated phosphorylation of LC3C and GABARAP-L2 controls autophagosome shedding by ATG4 protease

  • Authors: Herhaus, L. , Bhaskara, R.M. , Lystad, A.H. , Hummer, G. , Dikic, I.
  • Journal: EMBO Reports
  • Year: 2020

"SIK2 orchestrates actin-dependent host response upon Salmonella infection

  • Authors: Hahn, M. , Covarrubias-Pinto, A. , Herhaus, L. , Choudhary, C. , Dikic, I.
  • Journal: Proceedings of the National Academy of Sciences of the United States of America
  • Year: 2021

"TBK1 (TANK-binding kinase 1)-mediated regulation of autophagy in health and disease

  • Authors: Herhaus, L.
  • Journal: Matrix Biology
  • Year: 2021

"Recombinant Human Cytomegalovirus Expressing an Analog-Sensitive Kinase pUL97 as Novel Tool for Functional Analyses

  • Authors: Krämer, N. , Schütz, M. , Mato, U.G. , Marschall, M. , Zimmermann, C.
  • Journal: Viruses
  • Year: 2022

"The Autophagy Receptor SQSTM1/p62 Is a Restriction Factor of HCMV Infection

  • Authors: Krämer, N. , Mato, U.G. , Krauter, S. , Plachter, B. , Zimmermann, C.
  • Journal: Viruses
  • Year: 2024

Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Dr. Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Chungna National University | South Korea

Author Profile 

Scopus

Google Scholar

BIOGRAPHY OF SANG YEON CHO 🌟

EARLY ACADEMIC PURSUITS 🎓

Sang Yeon Cho embarked on his academic journey at Chungnam National University, where he earned his Bachelor's degree in Biochemistry in 2012. He further pursued an M.S. in Medicine, obtaining his MD degree in 2021. Currently, he is completing his Ph.D. in New Drug Discovery and Development, expected to graduate in February 2025. His strong foundation in the sciences has equipped him with the skills necessary for innovative research in the medical field.

PROFESSIONAL ENDEAVORS 🏥

Currently, Dr. Cho serves as the Vice Director of the Metro Neurosurgery Clinic in Daejeon, South Korea, since October 2022. Prior to this role, he was the Vice Director of Hurisarang Hospital from March 2021 to September 2022. His leadership positions reflect his commitment to advancing medical practice and enhancing patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON MOLECULAR CANCER BIOLOGY 🔬

As the Director of ChoLab since 2018, Dr. Cho has focused on cancer genomics and new drug discovery. His research has investigated the molecular mechanisms underlying cancer, emphasizing drug resistance and therapeutic targets. He has actively contributed to several labs, including the Neuroglia Lab and the Nano Primo Research Center, showcasing his multidisciplinary approach to tackling complex medical challenges.

IMPACT AND INFLUENCE 🌍

Dr. Cho's work has significantly influenced the field of medical genetics and cancer research. His publications in high-impact journals highlight the clinical significance of his findings, making substantial contributions to understanding cancer prognosis and treatment. Through his research, he aims to bridge the gap between laboratory discoveries and clinical applications, improving patient outcomes.

ACADEMIC CITATIONS 📚

His research output includes numerous peer-reviewed articles in respected journals such as BMC Medical Genomics, Scientific Reports, and BMC Cancer, where he explores topics like drug resistance, immunotherapy biomarkers, and cancer prognosis. His findings have garnered attention and citations within the academic community, underscoring the relevance and quality of his work.

LEGACY 🏆

Dr. Cho's dedication to advancing cancer research and patient care has already left a mark on the field. His innovative approach, exemplified by multiple patents related to AI in healthcare and cancer diagnostics, positions him as a forward-thinking researcher poised to shape future developments in medical science.

FUTURE CONTRIBUTIONS 🔮

Looking ahead, Dr. Cho aims to continue his research in cancer treatment and drug discovery, integrating cutting-edge technologies like artificial intelligence to enhance therapeutic strategies. With his expected Ph.D. completion in 2025, he is set to further expand his contributions to the field and inspire the next generation of medical researchers.

NOTABLE PUBLICATIONS 📑

"A method for the observation of the primo vascular system in the thoracic duct of a rat" 

  • Authors: Kim, S., Jung, S.J., Cho, S.Y., Soh, K.-S., Kim, S.
  • Journal: Evidence-based Complementary and Alternative Medicine
  • Year: 2013

"Protocol for the Observation of the Primo Vascular System in the Lymph Vessels of Rabbits" 

  • Authors: Jung, S.J., Cho, S.Y., Bae, K.-H., ... Song, Y.-K., Soh, K.-S.
  • Journal:  Journal of Acupuncture and Meridian Studies
  • Year: 2012

Bruno Fuchs | Sarcoma | Excellence in Innovation

Prof Dr. Bruno Fuchs | Sarcoma | Excellence in Innovation 

Swiss Sacroma Network | Switzerland 

Author Profile

Orcid ID

Bruno Fuchs, MD, PhD 🌟

Position: Professor and Chair, Sarcoma Center & Swiss Sarcoma Network

Location: Faculty of Health Science & Medicine, University of Lucerne, and LUKS University Hospital, Luzern, Switzerland

Contact: fuchs@sarcoma.surgery

Educational Background 🎓

  • 2022: Guest-Professor, Medical Faculty, University of Lucerne
  • 2010: Extraordinarius, Medical Faculty, University of Zurich
  • 2005: Associate Professor, Medical Faculty, University of Zurich
  • 2004: PhD in Biomedical Sciences (Tumor Biology), Mayo Graduate School, Mayo College of Medicine, Rochester, MN, USA
  • 1996 - 2004: Training and Fellowship in Orthopedic Surgery and Musculoskeletal Oncology at Mayo Clinic, Rochester, MN, USA, and Swiss institutions
  • 1992: MD, Medical Faculty, University of Zurich, Switzerland

Clinical and Research Expertise 🔬

  • Specializes in the surgical treatment of bone and soft tissue tumors in both pediatric and adult patients
  • Focuses on outcome analysis and quality indicators in sarcoma care
  • Engages in predictive outcome analytics for improving sarcoma treatment

Academic Contributions 📚

  • Authored over 200 publications and book chapters
  • Acquired over 10 million Swiss Francs in research funding
  • Active as a reviewer for prestigious journals and grant committees

Contributions and Research Focus on Sarcoma🏆

Fuchs has made profound contributions to the surgical treatment of bone and soft tissue tumors in both pediatric and adult patients. His research is heavily focused on the outcome analysis of sarcoma patients, defining and assessing quality indicators of sarcoma care, and predictive outcome analytics. His work is vital in improving the standards and methodologies employed in sarcoma care, directly impacting patient outcomes and care quality.

Public and Professional Service 🌐

  • Founder & Chair of the Swiss Sarcoma Network
  • Founder of the Sarcoma Academy
  • Member of multiple medical societies including SwissOrthopaedics, FMH, and CTOS

Dr. Bruno Fuchs is recognized internationally for his extensive contributions to the field of sarcoma research and treatment. His work continues to shape the future of musculoskeletal oncology.

Notable Publications📑

"Real-World-Time Data and RCT Synergy: Advancing Personalized Medicine and Sarcoma Care through Digital Innovation" 

  • Authors: Philip Heesen, Georg Schelling, Mirko Birbaumer, Ruben Jäger, Beata Bode, Gabriela Studer, Bruno Fuchs
  • Journal: Cancers
  • Year: 2024

"Improving Sarcoma Outcomes: Target Trial Emulation to Compare the Impact of Unplanned and Planned Resections on the Outcome" 

  • Authors: Timothy T. A. F. Obergfell, Kim N. Nydegger, Philip Heesen, Georg Schelling, Beata Bode-Lesniewska, Gabriela Studer, Bruno Fuchs
  • Journal: Cancers
  • Year: 2024

"Impact of Institutional Practices and Surgical Complexity on Sarcoma Surgery Costs: Driving Efficiency in Value-Based Healthcare"

  • Authors: Georg Schelling, Philip Heesen, Boris Malte Tautermann, Markus Wepf, Barbara Di Federico, Annika Frei, Kim van Oudenaarde, Pietro Giovanoli, Beata Bode-Lesniewska, Gabriela Studer et al.
  • Journal: Cancers
  • Year: 2024

"Development and Validation of the Bone Tumor Surgery Complexity Score"

  • Authors: Annika Frei, Georg Schelling, Philip Heesen, Pietro Giovanoli, Bruno Fuchs
  • Journal: Reports
  • Year: 2024

"Exploring Risk Factors for Predicting 30-Day Postoperative Morbidity in Musculoskeletal Tumor Surgery"

  • Authors: Philip Heesen, Maria Elyes, Jan Domanski, Georg Schelling, Sören Könneker, Bruno Fuchs
  • Journal: Journal of Clinical Medicine
  • Year: 2024